Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mink Therapeutics, Inc. (INKT)
:INKT
Holding INKT?
Track your performance easily
INKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.46 - $1.90
Previous CloseN/A
Volume98.55K
Average Volume (3M)164.61K
Market Cap
$32.97M
Enterprise Value$27.93M
Total Cash (Recent Filing)$299.04K
Total Debt (Recent Filing)$26.79M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 19, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding39,630,400
10 Day Avg. Volume142,057
30 Day Avg. Volume164,609
Standard Deviation0.23
R-Squared0.00035
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$6.50Price Target Upside638.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
MiNK Therapeutics News
PremiumCompany Announcements
MiNK Therapeutics Reports Q3 Growth and Strategic Advances
PremiumCompany Announcements
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board
Ownership Overview
3.54% Insiders
0.82% Mutual Funds
0.45% Other Institutional Investors
94.53% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INKT FAQ
What was Mink Therapeutics, Inc.’s price range in the past 12 months?
Mink Therapeutics, Inc. lowest stock price was $0.46 and its highest was $1.90 in the past 12 months.
What is Mink Therapeutics, Inc.’s market cap?
Mink Therapeutics, Inc.’s market cap is $32.97M.
When is Mink Therapeutics, Inc.’s upcoming earnings report date?
Mink Therapeutics, Inc.’s upcoming earnings report date is Mar 19, 2025 which is in 58 days.
How were Mink Therapeutics, Inc.’s earnings last quarter?
Mink Therapeutics, Inc. released its earnings results on Nov 14, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.03.
Is Mink Therapeutics, Inc. overvalued?
According to Wall Street analysts Mink Therapeutics, Inc.’s price is currently Undervalued.
Does Mink Therapeutics, Inc. pay dividends?
Mink Therapeutics, Inc. does not currently pay dividends.
What is Mink Therapeutics, Inc.’s EPS estimate?
Mink Therapeutics, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Mink Therapeutics, Inc. have?
Mink Therapeutics, Inc. has 39,630,400 shares outstanding.
What happened to Mink Therapeutics, Inc.’s price movement after its last earnings report?
Mink Therapeutics, Inc. reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -5.063%.
Which hedge fund is a major shareholder of Mink Therapeutics, Inc.?
Currently, no hedge funds are holding shares in INKT
---
MiNK Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (638.64% Upside)
$6.50 (638.64% Upside)
Hedge Fund Trend
Decreased
By 36.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.56%
12-Months-Change
Fundamentals
Return on Equity
78.50%
Trailing 12-Months
Asset Growth
-1.16%
Trailing 12-Months
Company Description
Mink Therapeutics, Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
---
INKT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with significant advancements in clinical trials, efficient cost management, and promising data presentations at SITC. However, concerns about the cash position and early stages of the GVHD program indicate areas that require attention.Read More>---
INKT Stock 12 Month Forecast
Average Price Target
$6.50
▲(638.64% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
AlloVir
―
Cardiff Oncology
―
Immatics
―
TScan Therapeutics
―
Lyell Immunopharma
―
Best Analysts Covering INKT
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-30.61%
assigned a buy rating 2 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -30.61% per trade.
---